Kurs & Likviditet
|2023-03-07||Extra Bolagsstämma 2023|
|2022-10-07||Extra Bolagsstämma 2022|
|2022-04-19||Ordinarie utdelning RAYTL 0.00 SEK|
|2021-04-20||Ordinarie utdelning RAYTL 0.00 SEK|
|2020-10-20||Extra Bolagsstämma 2020|
|2020-04-21||Ordinarie utdelning RAYTL 0.00 SEK|
|2019-04-23||Ordinarie utdelning RAYTL 0.00 SEK|
|Lista||Nordic SME Sweden|
October 1 - December 31, 2021
· Net sales SEK 45,462
· Operation profit SEK -5,503,595
· Profit after financial items SEK -5,490,108
· Earnings per share SEK -0,21
January 1 - December 31, 2021
· Net sales SEK 263,040
· Operation profit SEK -14,907,945
· Profit after financial items SEK -14,841,085
· Earnings per share SEK -0,58
· Cash and cash equivalents 2021-12-31 SEK 8,782,891
Number of shares
Per 2021-12-31, 25 558 597 shares
The Board proposes that no dividend be paid for the 2021 financial year.
Interim report Q1 2022 2022-05-27
Interim report Q2 2022 2022-08-26
Interim report Q3 2022 2022-11-25
Annual general meeting
The annual general meeting is scheduled for April 18, 2022at the company's premises at Olofsdalsvägen 40 in Halmstad, Sweden.
The annual report is planned to be available on the Company's website on April 11, 2022.
Significant events during the report period (2021-01-01 - 2021-12-31)
· Agreement with Careteq, Australia
· Million orders from Australia
· Gets MDR for Eazense of Läkemedelsverket, Sweden
· Granted patent for USA
· Signs agreement with ZleepZafe, GMBH receives orders of approximately SEK 4.4 million
· Order from Malmö municipality
Significant events after the end of reporting period
· Appoionts new CEO
· Restructing of business
Comments from CEO
New winds are blowing
As we have previously communicated, the focus in 2021 was sales to municipalities largely with the help of sales consultants, and the outcome in the form of orders and revenues has not been what was expected.
We are therefore changing our sales strategy towards municipalities in Sweden to partners where we already have a number of agreements in place. This frees up resources for an increase in sales efforts to partners both nationally and internationally.
Our sensor EaZense is today certified for the EU and covers the most important areas for digital supervision: case and presence detection. Our partner in Australia, Careteq, has around a hundred sensors in operation. They are now in the starting blocks for a stronger investment together with Raytelligence also in the USA. In Europe, a number of agreements have been concluded and negotiations are underway with some major players, where we are now in the final stages.
The automation that is constantly ongoing in the manufacturing industry has the consequence that planned maintenance of the machinery is of utmost importance for profitability and delivery capacity. To be able to do this, sensor systems are required that can measure the condition of the machines. With our radar technology developed for the healthcare field, we can offer a set of unique sensors for non-contact measurement to the manufacturing industry. We already have a certified sensor for measurement in e.g. packaging industry, this sensor will now be launched.
The sales cycles in the health area are long, which has resulted in us also investing in industrial applications. The development work that has been carried out and led to the EaZense system can also be applied to industrial applications.
With this strategy together with the fact that we reduce sales costs, we achieve positive cash flow much faster.
A very exciting development is that we have a dialogue with a European company about acquiring the rights to hardware solutions that would place us in a completely new position in the market. The consequence of this would be new functionality, high gross margins and safer deliveries in a time of component shortages.
The goal of selling 10,000 sensors by 2022 remains, deliveries are currently uncertain due to prevailing component deficiency.
The agreement with ZleepZafe GMBH has been terminated due to the other party not fulfilling the conditions
The parallel listing in Stuttgart ends on March 8, the decision was made due to small trading in the share.
I look forward to an exciting 2022 with a focus on revenue. Pelle Viberg, CEO
Questions are referred to:
Peter Martinson, CFO
+46 70 814 64 65
Raytelligence AB (publ)
302 41 Halmstad
This information is disclosed by Raytelligence AB under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on February 25, 2022, at 09:45 CET.
About Raytelligence AB (publ)
Raytelligence is a Swedish innovation company, based in Halmstad that offers products for monitoring vital parameters, ie breathing, heart rate and movement patterns, based on the company's own 60 GHz radar technology.